EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers

Sergei Noskov, Ekaterina Koksharova, Anna Arefeva, Veniamin Banko, Kseniia Radaeva, Iuliia Matvienko, Maria Gefen, Igor Makarenko, Roman Drai

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1497 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Sergei Noskov und 8 weiteren Autor:innen. Beteiligte Einrichtung: City Hospital No. 3, Yaroslavl, Russia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Insulin Lispro, Hypoglycemic Agents. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ultra‐rapid insulin lispro is an innovative insulin analogue designed to achieve rapid onset and short duration of action, aimed at optimizing glycemic control in patients with diabetes. This was a double‐blind, randomized, 2‐period, crossover clamp study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD), along with safety profiles, of a potential biosimilar ultra‐rapid insulin lispro compared to the reference product in healthy White men. A total of 35 healthy volunteers completed hyperinsulinemic euglycemic clamp procedures across both study periods. Blood samples were collected at predefined intervals up to 8 hours to assess PK parameters. Plasma glucose levels were monitored every 5 minutes during the 8‐hour clamps, with adjustments to the glucose infusion rate to maintain the target range. Insulin quantification in plasma was conducted using a validated enzyme‐linked immunosorbent assay method. PD assessment was based on glucose infusion rate profiles during both clamps. Geometric mean ratios for maximum plasma concentration and area under the concentration‐time curve from insulin administration to the last measurable concentration for the test and reference drugs fell within the bioequivalence range of 80%‐125%. Furthermore, the investigational drugs demonstrated comparable PK/PD profiles of insulin lispro. Both formulations exhibited similar safety profiles primarily characterized by mild injection site reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsInsulin LisproHypoglycemic AgentsHumansMaleGlucose Clamp TechniqueAdultTherapeutic EquivalencyCross-Over StudiesHealthy VolunteersDouble-Blind MethodYoung AdultBlood GlucoseArea Under Curve

Stichwörter der Autor:innen

bioequivalencecomparabilitydiabeteshyperinsulinemic euglycemic clampinsulin lisprophase I study

Substanzen

Biosimilar PharmaceuticalsInsulin LisproBlood GlucoseHypoglycemic Agents

Autor:innen und Institutionen

  • City Hospital No. 3, Yaroslavl, Russia.
  • Endocrinology Research Center, Moscow, Russia.
  • R&D Center, GEROPHARM, Saint-Petersburg, Russia.

Zitieren

APA

Noskov, S., Koksharova, E., Arefeva, A., Banko, V., Radaeva, K., Matvienko, I., Gefen, M., Makarenko, I., & Drai, R. (2025). Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1497

Vancouver

Noskov S, Koksharova E, Arefeva A, Banko V, Radaeva K, Matvienko I, et al. Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1497

BibTeX
@article{Noskov2025,
  author = {Noskov, Sergei and Koksharova, Ekaterina and Arefeva, Anna and Banko, Veniamin and Radaeva, Kseniia and Matvienko, Iuliia and Gefen, Maria and Makarenko, Igor and Drai, Roman},
  title = {Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1497}
}
Kostenlos starten →